The prostate-specific membrane antigen (PSMA; also known as glutamate-carboxypeptidase II—GCPII; NAALADase; folate hydrolase I—FOLH1) has been widely studied as a drug target for prostate cancer imaging and therapy [9–12]. This evidence concerns the gene FOLH1 and Familial prostate cancer.